Skip to main content

Table 2 Additional inclusion and exclusion criteria for patients in Group C

From: PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer

Inclusion criteria for patients in Group C
1. Bone marrow reserve adequate for chemotherapy (i.e. absolute neutrophil count (ANC) ≥ 1.5 × 109/l and platelet count ≥ 100 × 109/l)
2. Adequate creatinine clearance defined as GFR ≥ 50 ml/min
Exclusion criteria for patients in Group C
1. History of significant cardiac or other medical conditions that preclude the use of cisplatin and intravenous hydration
2. Clinically significant hearing impairment sufficient to affect daily living and/or pre-existing tinnitus
3. Pre-existing peripheral neuropathy that precludes the use of cisplatin
4. Hypersensitivity to the active substance or other platinum compounds or to any of the other excipients
5. Dehydrated condition